Memorial Sloan Kettering Cancer Center

Immix Biopharma adds Cleveland Clinic, UC Davis, and Sutter Health as clinical trial sites for its U.S. relapsed/refractory AL Amyloidosis trial, NEXICART-2, with Memorial Sloan Kettering Cancer Center as the lead site. The trial aims to evaluate CAR-T NXC-201's safety and efficacy, building on a 92% overall response rate from the ex-U.S. NEXICART-1 study.

FDA approved afami-cel, a T-cell receptor therapy, for metastatic synovial sarcoma. It uses genetically engineered T cells to target MAGE-A4 protein in cancer cells, showing tumor shrinkage in 43% of patients with a median response duration of 6 months. Similar to CAR T-cell therapies, it addresses a high need for new treatments in this rare cancer.

GI Innovation and Merck & Co (MSD) collaborate on a Phase II trial to assess GI-102 combined with Keytruda for metastatic liver cancer, melanoma, and renal cell carcinoma. The trial, conducted in South Korea and the US, aims to provide treatment options for patients resistant to immuno-oncology treatments.

Cancer drugs blocking IDO1 enzyme may also treat Alzheimer's by improving brain energy flow, protecting against toxic proteins in mouse models, suggesting potential repurposing for Alzheimer's treatment.

First patients enrolled in US pivotal study of AI-based image analysis module for lung cancer by Invenio Imaging, in collaboration with Johnson & Johnson and multiple cancer centers.

FDA grants accelerated approval for Tecelra (afamitresgene autoleucel) cell therapy for treating adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet specific HLA and MAGE-A4 antigen criteria. This marks the first engineered cell therapy for a solid tumor cancer approved in the U.S. and the first new therapy option in over a decade for synovial sarcoma.

Atara Biotherapeutics submits a Biologics License Application to the FDA for tabelecleucel (tab-cel®) as monotherapy for EBV+ PTLD patients who have received at least one prior therapy, with no FDA approved therapies in this setting. Tab-cel is an allogeneic, EBV-specific T-cell immunotherapy designed to target and eliminate EBV-infected cells, supported by pivotal data from over 430 patients. The therapy has Breakthrough Therapy and orphan drug designations, and has received marketing authorization in Europe, UK, and Switzerland under the brand name Ebvallo™.